Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Anne Andorn"'
Autor:
Amy T. Heath, Stephen R. Marder, John W. Newcomer, John G. Csernansky, James A. Graham, Robert A. Leadbetter, Anne Andorn, Anne Le Moigne, David P. Walling
Publikováno v:
The Journal of clinical psychiatry, vol 82, iss 5
Background: Positive and Negative Syndrome Scale (PANSS) data from a pivotal phase 3 study in participants with schizophrenia of RBP-7000, a recently marketed long-acting subcutaneous injectable risperidone formulation, were examined to determine if
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::028da48f85550c489ff5bdc51b2585b9
https://escholarship.org/uc/item/25s978bk
https://escholarship.org/uc/item/25s978bk
Autor:
Christian Heidbreder, Sunita Shinde, Jay Graham, Anne Andorn, Maurizio Fava, John W. Newcomer, John G. Csernansky, Gilbert Muma
Publikováno v:
Journal of Clinical Psychopharmacology. 39:428-433
Purpose/background The Phase 3 program for RBP-7000, a once-monthly subcutaneous (SC) extended-release risperidone formulation approved for treatment of schizophrenia, consisted of a double-blind placebo-controlled trial (previously reported) and a 5
Autor:
Anne Andorn, Paul J. Fudala
Publikováno v:
Substance Use Disorders
Buprenorphine is a mu-opioid partial agonist that was first developed as a parenteral analgesic and subsequently as a treatment for opioid dependence. In the United States, the first two products approved by the US Food and Drug Administration (in 20
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4a26d4c33b5194fea7e371c5f3c64511
https://doi.org/10.1093/med/9780190920197.003.0009
https://doi.org/10.1093/med/9780190920197.003.0009
Autor:
Barbara R. Haight, Norma Lynn Fox, Sunita Shinde, Anne Andorn, David R. Hassman, Paul J. Fudala, Susan M Learned, Christian Heidbreder, Vijay R Nadipelli, Daniel Rutrick, Y Zhao
Publikováno v:
Journal of Clinical Psychopharmacology
Supplemental digital content is available in the text.
Background BUP-XR (RBP-6000 or SUBLOCADE) is the first Food and Drug Administration–approved subcutaneously administered monthly extended-release buprenorphine medication for the treatment
Background BUP-XR (RBP-6000 or SUBLOCADE) is the first Food and Drug Administration–approved subcutaneously administered monthly extended-release buprenorphine medication for the treatment
Autor:
Jay Graham, David P. Walling, John W. Newcomer, Gilbert Muma, Maurizio Fava, John G. Csernansky, Anne Andorn, Sunita Shinde, Christian Heidbreder
Publikováno v:
Schizophrenia Bulletin. 45:S264-S265
BACKGROUND: RBP-7000 (PERSERIS™), a once-monthly subcutaneous extended-release risperidone formulation approved for the treatment of schizophrenia in adults, was designed to deliver clinically relevant plasma concentrations on the first day of dosi
Autor:
Fabrizio Micheli, Palmina Cavallini, Beatrice Oliosi, Cristiana Griffante, Christian Heidbreder, Massimo Bani, Manolo Mugnaini, John D. Beaver, Emilio Merlo Pich, Eugenii A Rabiner, Laura Iavarone, Anne Andorn, Chiara Savoia
Publikováno v:
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 38(2)
Selective dopamine D3 receptor (D3R) antagonists prevent reinstatement of drug-seeking behavior and decrease the rewarding effects of contextual cues associated with drug intake preclinically, suggesting that they may reduce drug craving in humans. G